Today: 20 March 2026
Browse Category

NASDAQ:VNDA 31 December 2025 - 23 February 2026

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.
Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

Nasdaq ends 2025 on a down note; markets closed today as jobs report, CPI loom

The Nasdaq Composite dropped 0.8% Wednesday to close 2025 at 23,241.99, while the S&P 500 lost 0.7% and the Dow fell 0.6%. U.S. markets are closed Thursday for New Year’s Day. Investors await the Jan. 9 jobs report, Jan. 13 inflation data, and the start of bank earnings for direction. Trading volume was below average, with tech and energy shares leading declines.
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.

Stock Market Today

  • European Stocks Rise as Oil Prices Drop and Rate Hike Bets Grow
    March 20, 2026, 5:11 AM EDT. European stocks rebounded on Friday, led by banking and construction sectors, as oil prices eased from recent highs above $119 a barrel. The decline followed U.S. signals about possibly lifting sanctions on Iranian crude to reduce energy costs. Central banks across Europe, including the European Central Bank (ECB) and Bank of England (BoE), held interest rates steady amid uncertainty from the U.S.-Iran conflict but traders increased bets on further rate hikes later this year. The ECB highlighted inflation risks tied to the war, while the BoE's unanimous hold hinted at readiness to act. Meanwhile, Unilever disclosed talks to sell part of its foods business to McCormick & Company, adding corporate activity amid market shifts.
Go toTop